Corporate Vice President for Discovery Biology & Technology
Novo Nordisk A/S
Dr. Søren Tullin is a Corporate Vice President and a member of Global Research management at Novo Nordisk A/S. Dr. Tullin is heading the Discovery Biology and Technology area which includes Novo Nordisk Research Center China (Beijing) as well as VP areas located in Denmark. The Discovery Biology and Technology area covers early target discovery, recombinant protein production, in vitro biology, pharmacology, bioanalysis, informatics/bioinformatics and antibody generation.
Dr. Tullin holds a Ph.D. in biochemistry from University of Copenhagen and has been with Novo Nordisk A/S for 26 years.
Dean, School of Innovation and Entrepreneurship | Director, Office of Science & Technology Development
Dr. Chen is the Director of Office of Business Development for Science and Technology, and a tenured full professor in the Faculty of Academy for Advanced Interdisciplinary Studies, Peking University, since Sept of 2011.
Dr. Chen oversees the university licensing and corporate sponsored research programs, and is leading the development of University’s entrepreneur and innovation teaching curriculum, a globalized collaborative technology transfer hub, and an open university-industrial joint research platform, university innovation parks and spin-off incubators throughout China.
Dr. Chen is a general partner for several seed funds of ~ 25Million USD per year for early stage projects investment in China from spin-offs based on University IP and international partners’ IP. Dr. Chen is also an angel investor and a general partner of Lightup Capital.
Dr. Chen is a vocal advocate for a strong enforcement of the intellectual property law and tougher penalty on IP infringers in China. Dr. Chen was elected as the International Advisor for World Intellectual Property Organization on the Globalized Innovation Index Research.
Dr. Chen is a Silicon Valley entrepreneur. He is the Chief Scientist and the inventor of the Metal Oxide Heteorjunction RRAM device of 4DS Inc. in Silicon Valley. He also co-founded Miradia Inc. in Silicon Valley in 2003 where he raised 80M USD from tier-1 venture capitals and led the development of a platform technology for MEMS-CMOS 3D integration for applications in digital micro-mirror array and motion sensors. He was responsible for company’s IP development Strategy and have build an IP portfolio of more than 100 international patents. He successfully licensed company’s patent portfolio to a major foundry in Asia.
Dr. Chen is the Board of Director, Sr. Advisor and former Chairman & President, of Chinese American Semiconductor Professional Association (CASPA).
Vice President Global Department Research Beyond Borders
M.S. Pharmacy, 1984, University of Amsterdam
Ph.D. Pharmacology, 1987 (University of Amsterdam)
Thesis entitled: Characterization and Classification of
Muscarinic Receptors and their Subtypes
Promotor: Prof. Dr. P.A. van Zwieten
July 1987 - Dec. 1988, Research Scientist,
Dept. of Pharmacology, Dr. Karl Thomae GmbH, Germany
Jan. 1989 - Oct. 1990, Group Leader,
Molecular Pharmacology, Dept. of Pharmacology,
Dr. Karl Thomae GmbH
Nov. 1990 – Dec. 2000 Director Cardiovascular Research Boehringer Ingelheim Pharma KG
Jan. 2001 –Dec. 2002
Head of Department Cardiovascular Research
Focus areas :thromboembolic diseases, hypertension, heart failure and obesity
Jan. 2003- June 2013
Director of the Pain Research Group
Focus areas : Migraine, Neuropathic pain , Inflammatory
pain and Viseceral pain
July 2013- Sept 2015
Vice President Respiratory Diseases Research
Research focus: COPD, Asthma, IPF, CF and ARDS
Since April 2015
Vice President Global Department Research Beyond Borders
Research Focus: Emerging science and novel technologies
Publications > 135 full publications
Patents: > 60
Global Head of External Drug Discovery at Global Discovery Chemistry
Novartis Institutes for BioMedical Research
Tobias Gabriel is the global head of external drug discovery at Global Discovery Chemistry, Novartis Institutes for BioMedical Research.
Prior to his current role Tobias was head of oncology chemistry, Basel and Shanghai.
Tobias joined Novartis six years ago from Roche where he held positions of increasing responsibility in medicinal chemistry in Palo Alto and most recently as Director of Research Strategy in Basel.
Tobias studied chemistry in Berlin and completed his Ph.D. in organic chemistry in Munich, followed by postdoctoral studies in nanotechnology at the Hebrew University of Jerusalem.
Chief Medical Officer and Vice President, Global Cardiology
Dr. Robert Kleiman is a board certified cardiologist and cardiac electrophysiologist who has performed research in both basic cellular electrophysiology as well as clinical electrophysiology. Dr. Kleiman completed his training at the University of Pennsylvania and was a member of a cardiology practice for 12 years before joining ERT in 2003. Dr. Kleiman is currently ERT’s Chief Medical Officer and Vice President, Global Cardiology. His responsibilities include oversight of ERT’s cardiology services, consulting with external clients and managing overall satisfaction of ERT’s global customers, including all aspects of ERT’s solutions.
Head of Innovation Center China, Drug Discovery
Tom received his PhD in organic chemistry from the University of Göttingen in 2008 where he studied reaction mechanism and selectivities using a combined computational and experimental approach. He then moved to the Massachusetts Institute of Technology as postdoctoral fellow, working on Palladium-catalyzed cross-coupling reactions. Tom joined Bayer in 2011 and worked for three years as lab head in medicinal chemistry in Wuppertal. In 2014, he moved to Berlin and became the assistent of the head of the Drug Discovery organization. Since January 2016, Tom is the head of the Innovation Center China, which identifies opportunities, aligns, and manages research collaboration projects between Bayer Drug Dicovery scientists and outstanding Chinese academic institutions as well as CROs. In 2001/2002, Tom spent one year in China, studying Chinese at Nanjing University and completing an internship in molecular biology at the Chinese Academy of Sciences in Shanghai.
Chief Executive Officer
Farrer Park Hospital, Singapore
Dr Timothy Low is CEO of Farrer Park Hospital, a private acute tertiary institution sited within Singapore’s first fully integrated healthcare and hospitality complex.
Prior to his current role, Dr Low served as CEO of Gleneagles Hospital in Singapore. Through his leadership, the hospital established itself as a 6-star private healthcare provider, clinching 14 local and regional awards including the prestigious Asian Hospital Management Award as well as the the ‘National Work Redesign Model Company’ by Spring Singapore (Governing agency for innovation in Singapore). Under him, revenues exceed 42% to over USD$100 million.
Having also served in senior management positions for pharmaceutical and medical device industries in the Asia Pacific region, Dr Low’s breath of exposure allowed him to pioneer the establishment of a global contract research organisation, validating Singapore as its regional headquarters.
SVP/COO of Lab Testing Division
Dr. Jason Liu is the Senior Vice President and head of Lab Testing Division at WuXi AppTec Inc, a global health care/CRO/biotech company. Dr. Liu is a seasoned executive with over 20 years of experience in clinical diagnostic, medical device, and life science Previously he worked at Hologic-Gen Probe, Life Technologies- Applied Biosystems, and Bio-Rad as business unit general manager at US headquarter, global portfolio leader, and regional GM for APAC and China.
Dr. Jason Liu received his Ph.D. in Molecular Biology & Human Genetics from Loma Linda University, MBA from Pepperdine University, and BA in Biochemistry from Shandong University.
Distinguished Professor, Endocrinology and Metabolism, Huashan Hosptial
Staff Scientist, Division of Endocrinology and Metabolism; Principal Investigator, Keenan Research Centre for Biomedical Science; Director of Islet Physiology Laboratory, St. Michael’s Hospital, University of Toronto.
Research in Dr. Wang’s lab is focused on understanding islet physiology, especially the regulation of islet cell secretion and function, as well as the mechanisms underlying beta-cell regeneration. One of his main research interests is the biology of GABA, and its actions in the regulation of glucose homeostasis. Efforts have been made in bridging the findings from their basic research to clinical settings. They are also studying the biology of GLP-1, an incretin hormone released from gut cells in response to feeding. Among patients with diabetes, when insulin production is insufficient, the release of GLP-1 is reduced. While seeking means of increasing pancreatic insulin production and enhancing GLP-1 action, other research areas include the signaling and molecular control of islet cell-to-cell interactions in regulating islet beta-cell function and glucose homeostasis during the development of diabetes. Dr. Wang’s research is both fundamental and translational, aimed at developing new therapeutic strategies that could enable patients with diabetes to permanently manage the disease and effectively avoid its associated complications.
Director and Dean
The National Center for Drug Screening and School of Pharmacy, Fudan University
Following medical practices in Shanghai, Dr. Ming-Wei Wang obtained his Ph.D. from University of Cambridge in 1989. He worked for a couple of US-based biotech companies a year later and served as a consultant to Merck and UNDP relative to China-related projects in the mid-1990’s. Thereafter, he was engaged in various entrepreneur activities. Dr. Wang joined the faculty of Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2001 and became Director of the National Center for Drug Screening in 2003. In 2004, he was named by Shanghai Pudong New District Government as a Senior Business Advisor. He founded the Chinese National Compound Library and has been its first director since 2012. Dr. Wang was appointed as Dean, School of Pharmacy, Fudan University in 2015. He is also an editorial board member of Trends in Pharmacological Sciences (TiPS), The Biochemical Journal, Acta Pharmacologica Sinica and Journal of Biomolecular Screening.
Chair Professor and Director, Institute of Molecular of Medicine
Dr. Rui-Ping Xiao is the Director of the Institute of Molecular of Medicine at Peking University and the Peking University Chair Professor. Dr. Xiao’s research has been focused on cardiovascular and metabolic diseases, with a major emphasis on a translational approach to take bench discoveries into clinically relevant situations. Ongoing research directions include signaling pathways involved in metabolic syndrome and associated cardiovascular complications. Currently, Dr. Xiao serves as a Council Member of the International Society of Heart Research and an Associate Editor of the New England Journal of Medicine and an Editorial Board Member of multiple international top journals.
Vice President, Head of Discovery Biology China
Novo Nordisk Research Centre China
Dr. Fang Zhang is Vice President, Head of Discovery Biology China at Novo Nordisk Research Center China.
Dr. Fang Zhang received B.S. degree from Tsinghua University in 1997 and Ph.D. degree from University of Utah in 2001. Since graduation, she has been focused on metabolic disease research and drug discovery at both biotech and pharmaceutical companies, including Metabolex, Inc, (USA), Eli. Lilly and Company (USA), and Novo Nordisk Research Centre (China). She has fifteen years of industrial experience in research and management for novel therapeutic discovery (large and small molecule), experience covering target discovery and validation, lead generation and optimization, in vitro and in vivo model development, pharmacology evaluation, and mechanism of action characterization. She holds strong passion on drug discovery and translational research for metabolic diseases.
Shenzhen Chipscreen Biosciences
Xian-Ping Lu,Ph.D., CEO & CSO, Chipscreen Biosciences Ltd., Shenzhen, China
Dr. Xian-Ping Lu founded Chipscreen Biosciences, the leading drug discovery and development company in China focusing on innovative small molecular therapeutics, 15 years ago with a group of US-trained professionals. Previously he was Director of Research at Galderma R&D (subsidiary of L’Oreal and Nestle) in Princeton until 2000, the year he became visiting professor at China’s State Key Laboratory for Biomembrane and Membrane Biotechnology in Tsinghua University. He also participated in founding Galderma Research Inc. and Maxia Pharmaceuticals in San Diego.
Dr. Lu came to the US in 1989 for postgraduate fellowship study at the Department of Pharmacology, University of California in San Diego, followed by research at La Jolla Cancer Research Foundation (Burnham Institute). He obtained his Ph.D. in Molecular Biology and M.S. in Biochemistry from Peking Union Medical College, Chinese Academy of Medical Sciences, and his B.S. degree in Biochemistry from Sichuan University.
With over 20 years of biomedical research and biotech/pharmaceutical experiences in various therapeutic areas, Dr. Lu is a skilled leader of diverse groups in global operating settings. He has published more than 80 peer-reviewed papers in prestigious journals including Natureand Science. He is the lead inventor of over 80 patented inventions in areas of small molecule therapeutics.
Chief Executive Officer
Dr. Jim Li is Chief Executive Officer at Sundia. In this role, Dr. Li is responsible for driving the company’s growth as one of China’s leading CROs.
Dr. Li has led a distinguished career in the pharmaceutical industry, having spent over 18 years at various companies including Henkel, Wyeth and Pfizer in the area of process research as well as medicinal chemistry. During his tenure, he was involved in a variety of drug discovery programs such as COPD, asthma, Rheumatoid/osteoarthritis, diabetes. Dr. Li also has co-authored more than 60 research articles and patents.
Dr. Li received his Ph.D in Organic Chemistry from University of Central Lancashire UK followed by a postdoctoral fellow at the University of Chicago with Dr. Philip Eaton.
SENIOR VP CARDIOVASCULAR AND METABOLIC DISEASES (CVMD) RESEARCH
Dr. Wang started his academic career as a postdoctoral researcher at Boston University in 1987. In 1992 he became an assistant professor at the University of Tennessee in Memphis where he worked until 1996. He has worked in several major Pharma (GSK, Roche, Schering/Bayer AG) as a Scientist, Senior Scientist, and Principle Scientist from 1990 to 2008 and in a start-up biotech (Arete Therapeutics, Inc.) as a Director of Pharmacology from 2008 to 2009.
In 2010, he joined CrownBio as the Head of CVMD Research. He has authored nearly 100 publications between research articles, invited reviewers, and book chapters, and has submitted patent applications in the areas of diabetes and metabolic diseases, heart and renal failure, hypertension, thrombosis, hemophilia, atherosclerosis and dyslipidemia, hemodynamics, pharmacokinetics and pharmacodynamics, safety pharmacology, etc. He has been involved in all stages of pharmaceutical R&D, from early stage target discovery and validation, to compound (large and small molecules) discovery, selection and profiling, IND filing, and clinical trials in Phase I & II.
Director, Search & Evaluation, JAPAC
Dr. Bin Li is currently Director, Search & Evaluation, JAPAC at AbbVie in Shanghai. Prior to joining global S&E team in July 2015, he was site head of AbbVie China R&D Center in Shanghai which focuses on pre-clinical drug discovery in several therapeutic disease areas including chronic kidney diseases. Dr. Li joined Abbott R&D Center, Shanghai in September of 2008 to head the center and carry out drug discovery research in several key therapeutic areas, and continued to head the center following separation of pharmaceutical business and formation of AbbVie. Prior to Abbott, Dr. Li was Vice President, Service Biology at ChemPartner to build and lead the service biology division. Before returning to Shanghai, he spent 16 years in US pharmaceutical and biotech companies, including Roche, Pfizer, Anadys, and Xceptor, with various titles from Research Scientist to Director to lead and support drug discovery research as well as drug screening and lead discovery technologies such as ATLAS, an affinity-based high throughput screening platform for protein ligand identification. Dr. Li received his B.S. from Lanzhou University in China in 1982, M.S. from Iowa State University in 1986, and Ph.D. from Penn State University in 1990. Dr. Li has more than 25 years of drug discovery experience in various therapeutic disease areas.
Chief IP Officer, National Engineering Research Center On Antibody Medicine
3SGuojian Pharmaceutical (Shanghai) CO., Ltd
Li Caihui is Patent Attorney\ Senior Engineer\Licensed Pharmacist
√ Sept. 1988-July 1992, Bachelor, Department of Pharmacy, Shenyang College of Pharmacy
√ Aug.-Oct. 1993, Synthesis of peptides Beijing Medical University
√ Feb. 2002, Training on IPRs AOTS training center( Tokyo Japan)
√ 25 cases of patent invalidation /administrative petition with MNC on antibodies and cleared up the patent obstacles on antibody in China.
√ Invalidation on ZL20061008639.X is honored as one of 10 national cases on patents reexamination and invalidation in 2014.
TenNor Therapeutics Limited
Ying Yuan received his Ph.D. in microbiology from the University of Montana. He did eight years of research on the biology and pathology of Chlamydia trachomatis and Mycobacterial tuberculosis at Rocky Mountain Laboratory of NIAID, NIH. After joining pharmaceutical industry in 1998, Dr. Yuan has been working in antibacterial discovery and development on small molecules and vaccines for both human and animal health. Dr. Yuan led multiple antibacterial discovery projects in Pfizer Inc. and he was the science lead to build Pfizer’s Anti-Infective Research Unit in Shanghai, China in 2011. Dr. Yuan opened his antibacterial consultant business, ABV-Advisors LLC. In 2015 and has been serving as an ad hoc reviewer in multiple study sections of NIH. Currently Dr. Yuan is the VP for preclinical study in TenNor Therapeutics Ltd. in Suzhou, China.
Shanghai Haiyan Pharmaceutical Technology Co., Ltd
Dr. Jiong Lan joined Yangtze River Pharmaceutical Group in 2013. He is General Manager of Shanghai Haiyan Pharmaceutical Technology Co., Ltd., Yangtze’s subsidiary focusing on innovative drug discovery and development.
Dr. Lan has led discovery and development of multiple new chemical entities in oncology, infection, and CNS therapeutic areas, among which 11 entered clinical trial development. He has more than 80 patents and articles published in filed-leading journals, including Clinical Cancer Research, Cancers Molecular Cancer Research, and Medicinal Chemistry Letters.
Before joining Yangtze, Dr. Lan served as director of medicinal chemistry department of Jiangsu Hengrui. Previously, Dr. Lan was recruited to Novartis based in San Francisco, US, where he worked on multiple kinase inhibitor programs in oncology department.
President and CEO
Sichuan PriMed Bio-tech Group Co., Ltd
President and CEO of Sichuan PriMed Bio-tech Group Co., Ltd. Toxicology professional committee of Chinese Pharmacological Society, Expert of new drug review of CFDA. Selected member of Chengdu Talents Pan (2014) and Sichuan Talents Plan (2015). She founded Non-human Primate Breeding Center in 2005. With over 20 years research experience in druggability of new compounds, NHP disease model and translational medicine, she has accomplished the drug effect evaluation of over 60 compounds with over 10 new drugs submitted to FDA and CFDA for IND application since 2008 when she began to conduct research on rhesus monkeys with naturally-occurring metabolic disease. During 2013 to 2016, she has established cooperation relations with big phamas such as Merck and research intuitions such as MRCT and Brown University.
Chengdu Hi-tech Zone Shanghai Office
Tony Pan is the Chief Representative of Chengdu Hi-tech Zone Shanghai Office. Prior to this position, he was the Chief Representative of CDHT San Francisco Office. Starting from 2004, Tony Pan was assigned to set up CDHT’s offices in Beijing, Shanghai and San Francisco. Before 2004, Tony was the office head of CDHT MOFCOM and the coordinator of Chengdu Intel Project Office.
Tony has been serving in Chinese government for 15 years helping multinational companies invest in China. He is proved capable of bridging between western and Chinese business practices and particularly solving thorny problems. Tony was one of the key persons helping Intel, Dell, Texas Instruments, SAP, Marvell, Alibaba, etc. for their investment in Chengdu. Tony is an expert on Chinese government affairs and strategy development for foreign companies. He was invited for speeches on Chinese development strategy, government affairs and regulatory compliance by JP Morgan, McCombs business school of University of Texas and University of San Francisco. Tony Pan holds LLB of Sichuan International Studies University and MBA of Fudan University.
Ningling Wang serves as the managing partner of the firm’s Shanghai office. Her practice involves patent prosecution, opinions, due diligence, client counseling, licensing, and patent litigation in the areas of chemicals, chemical engineering, pharmaceuticals, medical devices, semiconductor materials, 3D printing, and nanotechnology.
Ms. Wang has extensive experience working with multinational and Chinese companies, providing legal advice on IP portfolio management, due diligence, licensing, litigation, and trade secret protection and enforcement. She has been involved in various cases before the U.S. International Trade Commission (ITC) and U.S. district courts. She has also represented foreign companies with IP enforcement in China, including judicial and customs enforcement actions.
Ms. Wang speaks frequently at conferences and seminars in China and internationally on patent-related topics. She taught a graduate course on U.S. IP law at Renmin University of China Law School and a graduate course on U.S. IP law, with patent mock trial, at Shanghai Jiao Tong University KoGuan Law School. Ms. Wang also served as a program professor of law at China Science and Technology University.
Judy Lu graduated from Nanjing University, Shanghai Jiao Tong University ENBA and Holland business school MBA. From 2009 to 2011, She founded Shanghai JingYan Chemical Technology Co., Ltd, Shanghai LinkChem Technology Co., Ltd and HongKong YaHua Medical Technology Co., Ltd.
Judy Lu is fully responsible for the market and financing now. She got $10 million and $18 million venture capital in 2014 and 2016. Under her, annual revenues exceed $22 million.
President and COO
CVie Therapeutics Limited
Dr. Lit-Fui Lau, Ph.D., serves as President & Chief Operating Officer of CVie Therapeutics Limited. He is responsible for the daily operations and R&D activities of the company. Dr. Lau received his Ph.D. from the University of Connecticut Health Center and was a postdoctoral fellow at the Johns Hopkins University School of Medicine. Dr. Lau has 19 years of experience in a number of areas in the drug industry, ranging from discovery, clinical development to sales and marketing. He started his drug industry career at Pfizer Global R&D in the US and later joined the senior leadership team of the GSK R&D Center in China. Recently, Dr. Lau has been Vice President of R&D and General Manager at the Lee’s Pharmaceutical group before joining CVie Therapeutics Limited.
Senior Manager of Bio-chemical Division
Beijing East IP Ltd
Mr. Xiao is a senior patent attorney and litigator, and Senior Manager of the Biological & Chemical Division of Beijing East IP Ltd. Since joining Beijing East IP in 2002, Mr. Xiao has being helping many international companies in obtaining and protecting their IP rights in China. As a patent practitioner, Mr. Xiao has extensive experience of patent preparation, filing, prosecution and reexamination at the SIPO. Mr. Xiao also has abundant experience in litigating matters. Specifically, he has litigated dozens of cases before the Patent Reexamination Board, Beijing First Intermediate Court, Beijing IP Court and Beijing High Court, for various international companies including Pfizer, DSM, 3M, etc. His primary technical specialty covers pharmacy, life science, chemical engineering and chemistry.
Mr. Xiao received B.S. degree in Polymer Materials and Chemical Engineering in 1999, and M.S. degree in Organic Chemistry in 2002, both from Tsinghua University. Focusing on IP, Mr. Xiao also obtained LL.M. degree from the John Marshall Law School in Chicago in 2010.
Partner, Patent Attorney, Trademark Attorney, Lawyer
Shanghai Beshining Law Office
Mr. Wang is taking charge of Domestic Patent Department in Shanghai Beshining Law Office. Over 9 years of practice, he has handled hundreds of patent applications. He also successfully handled and won series of patent disputes in the field of chemical and pharmaceutical enterprises , including patent invalidation case referring to Fortune 500 chemical and pharmaceutical enterprises and patent administrative procedure retrial before the supreme court. In 2012, Mr. Wang participated in a training course of US patent law organized by Oliff & Berridge PLC, a famous intellectual property firm in US. Mr. Wang offers intellectual property services to many large chemical and pharmaceutical enterprises and research institutions. He has counseled hundreds of clients, including many well-known domestic and foreign large and medium New Drug R&D companies, Generic Drug Manufacture Companies, Pharmaceutical R&D process companies, R&D institutes such as Henkel KGaA, China National Pharmaceutical Group Corporation (Sinopharm), Shanghai Pharmaceuticals Holding Co.,Ltd, Shanghai Institute of Organic Chemistry under Chinese Academy of Sciences, Shanghai Institute of Pharmaceutical Industry, WuXi AppTec（Shanghai）Co, Ltd, Shanghai Chem Partner Co., Ltd, Shanghai Hisun Pharmaceutical Co. Ltd, Humanwell Healthcare (Group) Co.,Ltd, Yongning Pharma Co., Ltd, Fujian South Pharmaceutical Co., Ltd, Shanghai Morden Pharmaceutical Co. Ltd, Shanghai Zhongxi Pharmaceutical (Group) Co., Ltd, Shanghai Allist Pharmaceutical Co., Ltd, Lianhe Chemical Technology Co.,Ltd, AB Pharma Ltd, Viwit Pharmaceuticals Limited, ZAI Lab, Hisun Pfizer Pharmaceuticals Co., Ltd ,Arromax Pharmaceutical Technology (Suzhou) Co., Ltd, QR Pharmaceuticals Co., Ltd, Wuhan Kangpu Biological Medicine Co., Ltd, etc.
Mr. Wang got his B.S degree in Chemical Engineering from Jilin University, M.S. degree in Pharmaceutical Chemistry from Shanghai Institute of Materia Madica, Chinese Academy of Sciences (SIMM), and also got L.L.M degree in Intellectual Property from Shanghai University.
Executive Director, Biomedical Research Council
Agency for Science, Technology and Research, Singapore
Dr Benjamin Seet joined the Agency for Science, Technology and Research (A*STAR) in 2011 and assumed the appointment of Executive Director, Biomedical Research Council, one year later. Prior to joining A*STAR, he served the Singapore Armed Forces for more than 20 years, before retiring as the Chief of the SAF Medical Corps at the rank of Brigadier General. In addition, Dr Seet served as Chief Medical Officer of the United Nations Department of Peacekeeping Operations in New York from 2004 to 2006, where he oversaw medical support for UN personnel in 16 post-conflict countries.
Dr Seet was the founding Regional Secretary of the Asia Pacific Group of the International Committee of Military Medicine; co-chair of the ASEAN+8 Experts Working Group in Military Medicine; and led a UN Technical Advisory Group to Darfur, Sudan. He served as Visiting Consultant to the Ministry of Health; on the Boards of the Agri-food and Veterinary Authority, Health Promotion Board, and National Medical Research Council; on the Industrial Advisory Board of the School of Chemical and Biomedical Engineering at the National Technological University; and was formerly, Chairman of InVivos Pte Ltd.
Senior Director, Pharmaceutical & Biologics Cluster
Danny presently holds a dual position of Medical Director at A*STAR’s Drug Discovery and Development (D3) unit, and Senior Director at the Biomedical Research Council (BMRC). He previously worked at Eli Lilly and Company for 15 years in early phase clinical development, where he headed up the Lilly-NUS Centre for Clinical Pharmacology (LNUS). As the Managing Director and Principal Investigator, Danny had responsibility and oversight for all clinical Phase 1 studies conducted and operations in the unit. As an investigator, Danny was personally involved in over 90 clinical pharmacology studies, and oversaw over 130 studies at Lilly-NUS in various roles. This includes first-in-human studies, biomarker development work, human physiology investigations and pivotal registration PK studies, in neuroscience, diabetes, musculoskeletal and cardiovascular therapeutic areas.
Danny has deep experience in diabetes therapeutics development, including insulins. He established a high quality, high throughput clamp capability at LNUS, which has enabled LNUS to perform these niche studies in the support of Lilly portfolio, including several pivotal registration studies for the FDA.
In his current role in D3, Danny has responsibility for the early phase clinical programmes for novel therapeutics. At BMRC, Danny leads his cluster in working with biomedical research institutes to initiate and manage research programmes, in drug development, precision medicine and biomanufacturing, to drive industry relevant research.
Danny graduated with MBBS from NUS, and has a PG Dip in Drug Development Sciences from the University of Surrey.
Process Architecture Manager, China
Mr. Mark Stephens joined M+W Group in 2010 as a Project Manager / Process Architecture Manager. He is a Qualified Architect who specializes in the design and project management of technically complex scientific, pharmaceutical and radiopharmaceutical facilities. He has been directly responsible for concept design, design development, documentation, co-ordination and contract administration for various Australian, European, Chinese and International projects. Mark has a keen interest in sustainable design and the co-ordination of the structure and building engineering services to produce efficient and economical designs for his clients.
Director, Biologic drug development
Shanghai Hengrui Biopharmaceutical R&D
Dr. Zhuoxiao Cao is currently the director of biologic drug development at Shanghai Hengrui Biopharmaceutical R&D. She studied clinical medicine in China and got her PhD in Pharmacology in NY, followed by postdoc studies in Cardiology at Harvard Medical School. She has extensive experiences in biologic drug discovery and development in both international and domestic pharmaceutical companies. Prior to this role, she has been working in Novo Nordisk for five years focusing on inflammation drug development. She is now mainly responsible for mAb development projects in cancer immunotherapy and other disease areas and has led the team to achieve significant progresses. She was awarded as Shanghai Excellent Technology Leader and joint professor at Tongji University.
Johnson & Johnson Innovation Center AP
Dr. Mingde Xia is currently a Senior Director of Johnson & Johnson Innovation Center AP, and a vice Chair of Asian Society for Innovation & Achievement (A.S.I.A.) in USA and Canada. He focuses on business development in mainland China, Hong Kong, Taiwan, and Korea etc. with universities, institutes, investors and innovative companies for J & J worldwide pharmaceuticals, medical device / diagnostic products and OTC / consumer business, through investment, incubation, co-development, license and other collaboration vehicles. He has been working with Johnson & Johnson for 16 years after career track at China Pharmaceutical University and Yale University, and has successfully led / executed over 50 projects external collaboration for Johnson & Johnson three sectors. He is a guest / adjunct professor at the Chinese Academy of Sciences, a major inventor / author of over 60 patents / publications, a reviewer for a number of top quality international scientific journals, and an invited speaker for many international pharmaceutical conferences / forums. He received awards from American Chemical Society, Johnson & Johnson and different universities. He has actively involved in Sino-American Pharmaceutical Professionals Association (SAPA President 2009, Board of Directors 2008-2016) and organized many international conferences in USA and Asia.
Chairman & Chief Executive Officer
Zai Lab Limited
Dr. Du is a leading figure of China's biotech industry. She is the founder, Chairman and CEO of ZAI Lab, a premier innovative biopharmaceutical company in China. Prior to founding Zai Lab, Dr. Du was head of healthcare investments at Sequoia Capital China Fund and led the investments and served on the boards of Betapharma, BGI Tech, JHL Biotech, and Angel Healthcare, all of which made significant returns to the fund over her two years tenure there. Dr. Du is recognized as a pioneer of the China life sciences industry. As the CEO and founder of Hutchinson MediPharma, she spent ten years building a company with rich pipelines in oncology and autoimmune diseases. Under Dr. Du’s leadership, Hutchison MediPharma became the leader for innovative drug R&D in China, bringing five category 1.1 drugs into clinical trials - including the first drug into the CFDA green channel review process, and producing two global phase III ready programs. Dr. Du transformed the company into a global biotech company, and established unique collaboration partnerships with multinational companies including AstraZeneca, J&J, Lilly, Merck Serono and Nestle. Dr. Du was also the co-founder and CSO of Hutchison China Meditech, the first China based innovative drug company listed in overseas stock exchange with a current market cap of over $2 billion.
Prior to Hutchison, Dr. Du was responsible for Pfizer's global metabolic licensing program and was also involved in the development of multiple early and late stage products, of which two were approved by US FDA and launched globally. She received her Ph.D in Biochemistry from the University of Cincinnati.
Founder and CEO
Dr. Wen Luo is the founder and CEO of a leading precision medicine company, Denovo Biopharma. Dr. Luo has 20 years of experience in biomedical research and industry including more than 10 years of experience in applying genomic technology in drug discovery and development. Prior to joining Denovo Biopharma, Dr. Luo managed the genomic group and provided bioinformatic supports to a broad range of research projects across a number of therapeutic areas including oncology, hematology, inflammation and metabolic diseases at Ligand Pharmaceuticals. He was also responsible for developing clinical biomarkers for drugs in various stages of clinical trials. Before joining Ligand, he was senior bioinformatician at Incyte Genomic, where he managed one of the largest proteomic databases at the time, LifePro. He was also involved in discovering novel human genes and splice variants, and he was the co-inventor of patents covering 100s of novel genes derived from these findings. Prior to Incyte Genomics, he was a research scientist at Sugen (acquired by Pharmacia and then by Pfizer) working on drug target identification and validation for a number of novel kinases discovered at Sugen. Dr. Luo was a Howard Hughes Medical Institute post-doc fellow at UCSF, and received his Ph.D. in molecular biology and biochemistry from Indiana University School of Medicine. Dr. Luo received Pre-Med training at Peking University and medical training at Peking Union Medical College
Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences
Dr. Wu Jia-Rui, Professor of Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. He received a doctor degree from Swiss Federal Institute of Technology in Zurich, Switzerland, in 1994. Now, his lab is working on the molecular mechanisms of the diabetes and cancer by systems biology approaches. He has published more than 100 research papers in international scientific journals.
Dr. Wu’s academic appointments at present are as follows: Director of Key Laboratory of Systems Biology, CAS; Vice-President of Chinese Association of Geriatric Research. Dr. Wu has positions of academic service as follows: Editor-in-Chief for “Journal of Molecular Cell Biology”; Associate Editors for “BMC Systems Biology”, “Frontiers in Systems Physiology”.
VP, Clinical R&D
Dr. Yi Zhang heads the clinical research & development team at Hua Medicine，a company leading clinical-stage, innovative drug development in China, focusing on novel therapies for the treatment of diabetes and CNS disorders.
Prior to Hua, Yi was the Associate Medical Director of Clinical Science at Roche Product Development group, Asia Pacific region, working on innovative drug development in the areas of cardiovascular, metabolic and renal diseases. Prior to Roche, Yi was a Physician and an Associate Professor at Shanghai Ruijin Hospital, Shanghai Jiaotong University School of Medicine. She was also a team leader of the molecular genetics research group at Shanghai Institute of Hypertension and a principle investigator for several projects supported by the National Natural Science Foundation of China and the Shanghai Municipal Natural Science Foundation. She obtained MD and PhD from Shanghai Jiaotong University School of Medicine, specialized in cardiology. She received training in molecular genetics, bioinformatics and epidemiology as a NIH/NHLBI visiting researcher. She has received Shanghai Subject Chief Scientist and 60 publications in journals such as Nat Genet, Circ Cardiovasc Genet, Hum Mol Genet and has 3 China patents.
James Huang joined Kleiner Perkins Caufield & Byers China as a managing partner in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. James has made more than 15 investments in China since 2007.
Before coming to KPCB China, James was a managing partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. While at Vivo, James led numerous investments in China. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson).
James is Chairman of Board at Kindstar Global, JHL Biotech and XW Laboratory and Director at GenScript, ChiralQuest, Zenesis, CVie Therapeutics, CASI and Omni Pharmaceuticals.
James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley. He was born in Taipei， Taiwan.
Director, R&D External Innovation, Asia Pacific
Dr. Xichen Lin is currently Director of R&D External Innovation, Asia Pacific at Novo Nordisk. Prior to this role, he worked as Director of External Drug Discovery for the Neuroscience Unit of GlaxoSmithKline. He spent 14 years at GlaxoSmithKline, both in Philadelphia and Shanghai, holding various management positions including Head of Neuro-inflammation Discovery Performance Unit and Head of Chemistry, where he was responsible for delivering 6 clinical candidates within respiratory, inflammation and neuroscience areas. Dr. Lin received his B.S. degree from Peking University (China) and his Ph.D. degree from the Pennsylvania State University (U.S.A.).
Amy previously worked in Morningside Ventures for 13 years since 2002. She was in charge of Beijing office and invested and managed dozens of early staged biotech portfolios during this period. Up till now, most of the investments have exited via IPOs or M&A with multiple returns.
Prior to joining Morningside, she worked in GSK as regulatory manager for 5 years and product manager for 2 years.
Amy got her master degree in Chinese Academy of Sciences and bachelor degree from Shen Yang Pharmaceutical University. She is also a graduate of EMBA course of Cheung Kong Graduate School of Business (CKGSB).
Dr. Ni joined Frontline BioVentures in 2015 with over 15 years of experiences in life sciences sector as a research scientist, a business development executive and a venture capitalist.
Before joining Frontline BioVentures, she served as Managing Director with Rich-yield Capital and Director of Corporate Investment in Wuxi Apptec (NYSE:WX). At WuxiApptec, Dr. Ni was responsible for corporate strategic M&A and Wuxi’s proprietary venture capital fund. She led and participated investments including Foundation Medicine (FMI.Nasdaq), Agios (AGIO.Nasdaq), Callidus, TenNor Therapeutics and CF Pharmatech. Prior to WuxiApptec, Dr. Ni was Senior Manager of Business Development at Pfizer, initially in Japan for R&D partnership and alliance, and gradually expanding to product in-licensing, collaboration, strategic investment and M&A for Pfizer’s Animal Health Division (now Zoetis) in Asia Pacific Region. As a biologist by training, Dr. Ni’s career started at Bayer Pharmaceutical’s Drug Discovery Center in Kyoto Japan. Dr. Ni obtained her B.S. of biology from East China Normal University, and then Master and Ph.D. in Pharmaceutical Sciences from Osaka University in Japan.
Lilly Asia Ventures
Dr. Hongbo Lu currently is a partner at Lilly Asia Ventures. Previously, Dr. Lu was with OrbiMed Advisors (2011-2016), serving as the Managing Director in Asia and responsible for over $500m public equity investment portfolio in emerging markets that generated an estimated double digit annualized returns, during the four years between 2012-2015, significantly outperforming the emerging market index benchmark (-15% decline over 2011-2015). In addition, Dr. Lu also led a few private equity investments and served as board of directors including EchoSens (France) and Crown Bioscience. Dr. Lu has over 15 years of investment and operational experience in healthcare industry in the US and in China, including her tenures at OrbiMed, Piper Jaffray & Co. and Zyomyx. At Piper Jaffray & Co. (2005-2011), Dr. Lu started as a biotech analyst covering then mid/small cap US biotech companies including Gilead, Celgene, Vertex, Regeneron, Alexion, etc., before taking the responsibility to lead Piper's China healthcare equity research team in Asia. Prior to her Wall Street career, Dr. Lu spent several years in life science start-up operations and business development at Zyomyx, Inc., a proteomics company in the Bay Area. Dr. Lu received a Ph.D. in BioEngineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and graduated with honor from Tsinghua University in China.
founder and CIO
ABG-LB Healthcare Fund
Dr. Bin Li is the founder and CIO of ABG-LB Healthcare Fund and a partner of Ally Bridge Group, a global healthcare investment fund based in Hong Kong. Previously, he was a Managing Director and the Head of Greater China Healthcare Research at Morgan Stanley and led the coverage of Greater China healthcare industry. Since he moved to Morgan Stanley and established the healthcare research practice in Hong Kong in 2008, he had been ranked as the top analyst in China healthcare industry by the most widely recognized investor surveys. He was ranked No. 1 Asia Healthcare Analyst by the Institutional Investor (II) for seven consecutive years (2008-2014) and No.1 China Healthcare Analyst each year by II since the poll started in 2010 (2010-2014). He was also repeatedly ranked as No. 1 Asia Healthcare Analyst by all other independent investor surveys including Greenwich and Asiamoney. In addition, he was rated as No. 1 in Wall Street Journal's Best Asia Healthcare Analysts poll for his stock selection in 2010. Before joining Morgan Stanley, he was a senior healthcare research analyst at Merrill Lynch (Hong Kong) and responsible for the firm’s stock research efforts on Asia healthcare. Before moving to Hong Kong in 2007, he was a key member of a top-rank US pharmaceutical research team at Merrill Lynch based in New York.
Dr. Li has over 20-year experience in healthcare industry. He received his Ph.D. in biochemistry and MBA from New York University and bachelor degree from Fudan University, China. Prior to his sell-side career, he worked at Merck Research Laboratory as a scientist and published papers on peer-reviewed science journals.
CSO and Head of Clinical R&D, R&D Institute
Sanhome focuses innovative drug discovery in the therapeutic areas such as oncology (target/I-O), infectious diseases and neurological disorders. Dr. Ling oversees early target discovery, screening/evaluation and pre-clinical development, and is leading clinical R&D and BD to identify and develop new projects. Dr. Ling was a physician practiced in China for 6 years, and holds a Ph.D. in pharmacology from Wuerzburg University, Germany. He was a Harvard faculty, an alumnus of Genzyme, Sanofi and Abbvie, with 50+ publications, and has been with Sanhome since 2016.
Senior Director of Business Development
Dr. Will Liu is the Senior Director of Business Development at GlaxoSmithKline. He
serves the roles of Worldwide Business Development Head for Neurosciences and
Head for Asia. His responsibilities include establishing and implementing the business
development strategy for Neurosciences globally, as well as partnering with biotech
companies and academia in Asia.
Dr. Liu has 20 years of experience in the pharmaceutical industry. Prior to joining GSK,
he had served in similar capacities at Merck Healthcare and Bayer Healthcare, where he
was responsible for establishing a number of strategic partnerships, including the ones
with Tsinghua University and Peking University.
Dr. Xi began his chemistry career at Peking University and received a PhD degree from Rice University. After working as a postdoctoral associate at Rice University and a senior research chemist at AMRI in Albany, New York, he joined Amgen Inc. in Thousand Oaks, California in 1998. In 2008, Dr. Xi moved to Guangdong and is now Chief Scientific Officer at HEC Pharma, Guangdong. Currently he directs several drug discovery and development programs in cancer and anti-inflammatory fields. Drug candidates generated from his team are in Phase I clinical trial (ongoing and finished, in China) and in preclinical development stages. Dr. Xi has published 50 research papers and 65 patents or patent applications. He is an expert in the national “The Recruitment Program of Global Experts (Thousand-Expert Plan)”, a team leader for “Innovative Drug Discovery Team from Overseas”, Guangdong Province, and a principal investigator for national “Major Drug Discovery and Development Programs” in “Twelves Five-Year Plan”, and an adjunct professor in Jilin University.